Complete Revascularization with pVAD vs IABP
Analysis Showcases Potential for More Complete Revascularizations with Impella® Heart Pumps Compared to IABP during HRPCI
This page gives you an overview about the York data analysis - a pooled Individual Patient Data (IPD) comparison of pVAD and IABP in High-Risk PCI, presented by Vasileios Panoulas, MD, at EuroPCR 2023 (York I) and ESC 2023 (York II).
York I: Complete Revascularization with pVAD vs IABP
In Part 1 of the pooled data analysis led by the York Health Economics Consortium, Vasileios Panoulas, MD, and colleagues examined data from PROTECT II, PROTECT III, and RESTORE EF to explore the hypothesis that using a percutaneous LVAD, such as Impella® heart pumps, during high-risk percutaneous coronary intervention (HRPCI) helps achieve more complete revascularization compared to HRPCI supported with an intra-aortic balloon pump (IABP).
York II: Acute Coronary Syndromes and High-Risk PCI: State of the Art
In Part 2 of the York data analysis, Dr. Panoulas and colleagues looked at data from PROTECT II and RESTORE EF to investigate the relationship between completeness of revascularization, NYHA heart failure class, and 90-day LVEF in patients undergoing HRPCI with either Impella or IABP.
York Data Analysis About Complete Revascularization With pVAD vs IABP: York I vs York II - A Comparison
Learn more about the differences and key points between part I and part II of the York data set.
Complete Revascularization with pVAD vs IABP
At EuroPCR 2023, Vasileios Panoulas, MD, presented results of a third-party analysis comparing complete revascularization (CR) rates in high-risk PCI patients who received Impella support compared to intra-aortic ballooon pump (IABP) support.
Acute Coronary Syndromes and High-Risk PCI: State of the Art
Vasileios Panoulas, MD, and colleagues pooled individual patient data from the PROTECT II randomized controlled trial and the RESTORE EF study and found that baseline SYNTAX score, residual SYNTAX score (rSS), and LVEF at baseline were significant predictors of NYHA class at 90 days after high-risk PCI.
A “Treasure Trove” of Complete Revascularization Data
Vasileios Panoulas, MD, discusses an individual patient data pooling from the PROTECT II RCT, PROTECT III, and RESTORE EF trials released at EuroPCR 2023.
ESC 2023: Predictors of 90-day Outcomes from York Analysis
Vasileios Panoulas, MD, discusses a pooled analysis of factors predicting outcomes at 90 days in high-risk PCI patients.
Learn More About Clinical Evidence Related to Impella
NPS-3763